论文部分内容阅读
食管癌是我国常见高发恶性肿瘤之一,大部分患者确诊时已发生局部侵犯或远处转移,而姑息性化疗是晚期食管癌患者的主要治疗手段。一线化疗后疾病进展且一般状况良好的患者仍需要接受二线治疗,然而目前尚无标准的二线化疗方案,故寻找一线化疗失败后的解救治疗方案就显得尤其的重要。近十多年来,许多新药包括多西紫杉醇、伊立替康及吉西他滨等已被试验用于晚期食管癌的化疗,而随着分子靶向药物的进步,也为食管癌的内科治疗提供了新的治疗途径。
Esophageal cancer is one of the most common malignant tumors in our country. Most of the patients had local invasion or distant metastasis at the time of diagnosis. Palliative chemotherapy is the main treatment for patients with advanced esophageal cancer. However, after the first-line chemotherapy, patients with advanced disease are generally still in need of second-line treatment. However, there is no standard second-line chemotherapy currently. Therefore, it is particularly important to find a first-line rescue after the failure of chemotherapy. For more than a decade, many new drugs, including docetaxel, irinotecan and gemcitabine, have been tested for the treatment of advanced esophageal cancer, and as molecular-targeted drugs have progressed, they have also provided new medical treatments for esophageal cancer Therapeutic approach.